Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine and Oxybutynin Effect on Cognition in Elderly OAB Patients with MCI
NCT02240459Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Aug 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fesoterodine in overactive bladder (OAB), sponsored by University of Alberta. Started Aug 2016; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02240459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240459.